FDA Guidance for Expedited Programs For Serious Conditions


FDA updates guidelines to expedite the development and review of new drugs.

FDA updates guidelines to expedite the development and review of new drugs.

The FDA just released its guidance for industry regarding expedited programs for serious conditions. There are four FDA programs intended to expedite the development and review of new drugs to address unmet medical need in the treatment of a serious or life-threatening condition. They are: 1) fast track designation, 2) breakthrough therapy designation, 3) accelerated approval, and 4) priority review designation.

Fast Track Designation

Drug to treat a serious disease and fill an unmet medical need.

Key Points

  • Designation may be granted on the basis of preclinical or clinical data
  • Process designed to facilitate development and expedite review
  • Fast Track designated drugs are eligible for: More frequent interactions with FDA (meetings or written correspondence) during drug development Rolling review, whereby companies can submit completed sections of marketing applications for FDA review, rather than waiting until every section is complete

Breakthrough Therapy Designation

Drug intended to treat a serious or life-threatening disease in which there is currently a treatment available.

Click here to read the full article on Rare Disease Report.

Related Videos
Hand holding a Narcan Evzio Naloxone nasal spray opioid drug overdose prevention medication
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.